
Swati Mamidanna, MD
@swatimamidanna
Budding Radiation Oncologist
📍Rutgers Cancer Institute of New Jersey
ID: 1574718380791287808
27-09-2022 11:11:46
12 Tweet
32 Followers
70 Following

Rutgers RadOnc residents after Dr. Deek’s lecture on Anal Cancer. Rutgers Radiation Oncology Residency Program Matthew P Deek Jennifer Betourney Jongmyung Kim, MD PhD


.Rutgers Cancer Institute’s Dr. Bruce Haffty Bruce Haffty & colleagues present “Conservation Tx on Local Recurrence in Pts w/ Multiple Ipsilateral #BreastCancer: Results from ACOSOG Z11102 (Alliance)” @ #SSO2023 eventscribe.net/2023/SSO/agend… RWJBarnabas Rutgers RWJMedSchool Rutgers Radiation Oncology Residency Program Robert Wood Johnson University Hospital Society of Surgical Oncology #BCSM


🙏 Rutgers Radiation Oncology Residency Program residents and Bruce Haffty for inviting me to Rutgers Cancer Institute as a #radonc visiting professor! Really enjoyed reviewing cases and answering your questions about leadership, culture and education! Ron Ennis, M.D. ARRO


.Rutgers Cancer Institute’s Dr. Bruce Haffty Bruce Haffty, Dr. Maria Kowzun Maria Kowzun. Dr. Mridula George Mridula George, Dr. Nisha Ohri, Dr. Shicha Kumar, Dr. Swati Mamidanna Swati Mamidanna, MD & Dr. Lindsey Potdevin present “PO5-22-02 Evaluation of ...” at #SABCS23. sabcs.org/FullProgram



Novel approaches to #prostatecancer #radiotherapy at the Presidential Symposium #ASTRO24. Practical approaches to both salvage after primary recurrence and oligometastatic disease by Ronald Chen and Dr Phuoc Tran. #pcsm #radonc


#ASTRO24 Rutgers Cancer Institute Rutgers Radiation Oncology Residency Program. Our fantastic residents and medical students in DC. So proud of our trainees! Lakshmi R Narra Swati Mamidanna, MD Ahmed Shalaby, MD


We are proud that 3 of the 4 plenary talks at ASTRO had authors from Rutgers Radiation Oncology Residency Program Rutgers Cancer Institute @bhaffty Salma Jabbour Rahul R. Parikh, MD, MBA Congrats to all. Amazing.

#ASTRO24 Kristin Higgins ASTRO Plenary: limited stage small cell lung ca chemoradiation with/without atezolizumab showing no improvements with in survival rates with the addition of atezo compared to CRT. Possible benefit with BID RT
